

Closed Session Minutes
of the
Maryland Commission on Kidney Disease
October 24, 2019

Upon motion made in public session, Chairman Hanes called for adjournment of the Public Session into closed session to discuss the following items:

1. Discussion of Confidential Pricing of Hepatitis C antiviral medications requested to be added to the Kidney Disease Program's Formulary- Authority: General Provisions Article, §§ 3-305(b)(7) and 3-103(a)(1)(i).

The Closed Session was called to order at 4:21 p.m. and held under the authority of § 3-104 of the General Provisions Article.

In attendance, in addition to Chairman Hanes, were Commissioners' Costa, Guthrie, Harris, Berliner, Korgaonkar, Leon, Rayfield, Hires, Townsend, Thavarajah, and Yospin were present.

In attendance representing Staff was Eva Schwartz, Executive Director and Donna Adcock, RN, Surveyor.

Also attending was Leslie Schulman, Commission Counsel.

Item One

The Commission discussed pricing issues associated with adding Hepatitis C (Hep-C) antiviral medications to the Kidney Disease Program's (KDP) Formulary used for the treatment of Hepatitis C. After discussing the issues and lack of specific data to make any conclusions as to drug efficacy, and after consulting with counsel, it was decided that it was premature to act on adding Hep-C antiviral medications without a formal request by a Pharmaceutical company to have the Kidney Disease Program add a specific drug to the formulary (Authority: General Provisions Article, §§ 3-305 (b)(7) 3-103 (1)(1)(i).

Upon Motion made, the Closed Session was adjourned at 4:44 p.m.